© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Medicenna Therapeutics Corp. (MDNA) shows an Average True Range (ATR) of N/A and an Enterprise Value of N/A. Its average trading volume over the past 3 months is N/A, indicating liquidity. These fundamental metrics provide insight into MDNA's underlying financial health and market activity.
Medicenna Therapeutics Corp. (MDNA) technical indicators as of January 1, 2026: the SMA 20 is N/A, SMA 50 at N/A, and SMA 200 at N/A. The RSI 14 value is N/A, suggesting its current momentum. These technical analysis signals help assess MDNA's price trends and potential future movements.
Medicenna Therapeutics Corp. (MDNA) stock performance overview as of January 1, 2026: The 52-week high is $0.2 (currently N/A below), and the 52-week low is $0.151 (currently N/A above). Over the past year, MDNA's performance is -75.47%, compared to the S&P 500's 12.29% change.
According to market data, Medicenna Therapeutics Corp. (MDNA) stock's recent performance metrics show that over the last month, MDNA is -21.88%, with a Year-to-Date (YTD) performance of -56.41%. Over the past year, the stock has seen a -75.47% change. These figures summarize MDNA's price movements across various periods, reflecting its historical returns.
According to current financial data, MDNA stock's P/E (TTM) ratio is 9.01, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for MDNA, including P/S (N/A), P/B (0.47), and P/FCF (N/A), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.